Iovance owns more than 40 U.S. patents related to TIL therapy, including patents directed to compositions and methods of treatment in a broad range of cancers, such as U.S. Patent Nos. 10,130,659; 10,166,257; 10,272,113; 10,363,273; 10,398,734; 10,420,799; 10,463,697; 10,517,894; 10,537,595; 10,639,330; 10,646,517; 10,653,723; 10,695,372; 10,894,063; 10,905,718; 10,918,666; 10,925,900; 10,933,094; 10,946,044; 10,946,045; 10,953,046; 10,953,047; 11,007,225; 11,007,226; 11,013,770; 11,026,974; 11,040,070; 11,052,115; 11,052,116; 11,058,728; 11,083,752; 11,123,371; 11,141,438; 11,168,303; 11,168,304; 11,179,419; 11,202,803; 11,202,804; 11,241,456; 11,254,913; 11,266,694; 11,273,180; 11,273,181.
Iovance also owns U.S. patents covering TIL manufactured from a tumor digest and the use thereof, such as U.S. Patent Nos. 11,007,225; 11,007,226; 11,052,115; 11,052,116; 11,058,728; 11,083,752; 11,123,371;11,141,438; 11,179,419; 11,202,803; 11,202,804; 11,241,456; 11,254,913; 11,266,694; 11,273,180; 11,273,181;and others. U.S. Patent No. 11,058,728 specifically covers a method of treatment using expanded TILs manufactured from a tumor digest where the expansion steps through the step of cryopreservation of the infusion bag having a harvested TIL population are performed within about 24 days. U.S. Patent No. 11,123,371 specifically covers a cryopreserved TIL composition comprising expanded TILs manufactured from a cryopreserved tumor digest where the expansion steps through the step of cryopreservation of the infusion bag having a harvested TIL population are performed within about 24 days. U.S. Patent No. 11,141,438 specifically covers an expanded population of TILs manufactured from a cryopreserved tumor digest where the expansion steps through the harvest step are performed within about 24 days. U.S. Patent No. 11,179,419 specifically covers a method for expanding TILs from a cryopreserved tumor digest where the expansion steps through the step of cryopreservation of the infusion bag having a harvested TIL population are performed within about 24 days.
Iovance holds an exclusive license from NIH of certain rights under U.S. Patent No. 11,077,182 and additional allowed U.S. patent applications covering methods of treating HPV+ cancers in a patient with T-cells expanded from HPV+ tumor fragments obtained from the patient.
Furthermore, Iovance owns U.S. patents covering the use of the combination of TIL therapy and an anti-PD-1 antibody, such as U.S. Patent No. 10,272,113, or an anti-PD-L1 antibody, such as U.S. Patent No. 11,013,770.
